| Polymorphism in the Pharmaceutical Industry: Solid Form and Drug Development R Hilfiker, M Von Raumer John Wiley & Sons, 2019 | 1226 | 2019 |
| Facts and fictions about polymorphism AJ Cruz-Cabeza, SM Reutzel-Edens, J Bernstein Chemical Society Reviews 44 (23), 8619-8635, 2015 | 675 | 2015 |
| Pharmaceutical stress testing: predicting drug degradation SW Baertschi, KM Alsante, RA Reed CRC Press, 2016 | 442 | 2016 |
| Hydrogen bond directed cocrystallization and molecular recognition properties of acyclic imides MC Etter, SM Reutzel Journal of the American Chemical Society 113 (7), 2586-2598, 1991 | 310 | 1991 |
| Characterization of the solid state: quantitative issues GA Stephenson, RA Forbes, SM Reutzel-Edens Advanced drug delivery reviews 48 (1), 67-90, 2001 | 277 | 2001 |
| Physical characterization of polymorphic drugs: an integrated characterization strategy L Yu, SM Reutzel, GA Stephenson Pharmaceutical Science & Technology Today 1 (3), 118-127, 1998 | 271 | 1998 |
| Characterization of the “hygroscopic” properties of active pharmaceutical ingredients AW Newman, SM Reutzel‐Edens, G Zografi Journal of pharmaceutical sciences 97 (3), 1047-1059, 2008 | 219 | 2008 |
| Crystallization and polymorphism of conformationally flexible molecules: problems, patterns, and strategies L Yu, SM Reutzel-Edens, CA Mitchell Organic Process Research & Development 4 (5), 396-402, 2000 | 211 | 2000 |
| Self-organization of adenine and thymine in the solid state MC Etter, SM Reutzel, CG Choo Journal of the American Chemical Society 115 (10), 4411-4412, 1993 | 200 | 1993 |
| Can computed crystal energy landscapes help understand pharmaceutical solids? SL Price, DE Braun, SM Reutzel-Edens Chemical Communications 52 (44), 7065-7077, 2016 | 175 | 2016 |
| Anhydrates and hydrates of olanzapine: crystallization, solid-state characterization, and structural relationships SM Reutzel-Edens, JK Bush, PA Magee, GA Stephenson, SR Byrn Crystal growth & design 3 (6), 897-907, 2003 | 159 | 2003 |
| Assessment of the amorphous “solubility” of a group of diverse drugs using new experimental and theoretical approaches L Almeida e Sousa, SM Reutzel-Edens, GA Stephenson, LS Taylor Molecular pharmaceutics 12 (2), 484-495, 2015 | 155 | 2015 |
| A prolific solvate former, galunisertib, under the pressure of crystal structure prediction, produces ten diverse polymorphs RM Bhardwaj, JA McMahon, J Nyman, LS Price, S Konar, IDH Oswald, ... Journal of the American Chemical Society 141 (35), 13887-13897, 2019 | 143 | 2019 |
| Exploring the experimental and computed crystal energy landscape of olanzapine RM Bhardwaj, LS Price, SL Price, SM Reutzel-Edens, GJ Miller, ... Crystal growth & design 13 (4), 1602-1617, 2013 | 139 | 2013 |
| Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine DM Bender, J Bao, AH Dantzig, WD Diseroad, KL Law, NA Magnus, ... Journal of medicinal chemistry 52 (22), 6958-6961, 2009 | 129 | 2009 |
| The potential of computed crystal energy landscapes to aid solid-form development SL Price, SM Reutzel-Edens Drug Discovery Today 21 (6), 912-923, 2016 | 104 | 2016 |
| Coamorphous active pharmaceutical ingredient–small molecule mixtures: considerations in the choice of coformers for enhancing dissolution and oral bioavailability A Newman, SM Reutzel-Edens, G Zografi Journal of pharmaceutical sciences 107 (1), 5-17, 2018 | 91 | 2018 |
| Supersaturation potential of salt, co-crystal, and amorphous forms of a model weak base L Almeida e Sousa, SM Reutzel-Edens, GA Stephenson, LS Taylor Crystal Growth & Design 16 (2), 737-748, 2016 | 89 | 2016 |
| Contrasting polymorphism of related small molecule drugs correlated and guided by the computed crystal energy landscape DE Braun, JA McMahon, LH Koztecki, SL Price, SM Reutzel-Edens Crystal growth & design 14 (4), 2056-2072, 2014 | 89 | 2014 |
| Accuracy and reproducibility in crystal structure prediction: the curious case of ROY J Nyman, L Yu, SM Reutzel-Edens CrystEngComm 21 (13), 2080-2088, 2019 | 81 | 2019 |
